WARSAW, Ind., May 10, 2018 /PRNewswire/ — DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced clinical findings outlining the potential benefits patients may experience when undergoing knee replacement with the ATTUNE Knee System.

First, a study¹ presented at the 2^nd World Arthroplasty Congress in Rome on Patient Reported Outcome Measures (PROMS) reported a statistically significant improvement in knee physical function at six months with the ATTUNE Knee compared to preoperative baseline, using the Knee injury and Osteoarthritis Outcome Score-Physical Function Short Form (KOOS-PS). The multicenter study of 200 cases from The Netherlands found that 80 percent of those ATTUNE Knee patients’ KOOS-PS improvements were realized by six months, with statistically significant improvements observed at intervals prior to six months. Also, pain and other PROMS were statistically significantly better at six weeks compared with pre-operative baseline.

“This multi-center outcomes study is further evidence of the positive performance of the ATTUNE Knee, and this study provides additional evidence on the rate of recovery – information that is useful when counseling patients before surgery,” said Geert Meermans, MD, Bravis Hospital, The Netherlands. “From my intraoperative and patient follow up experiences, the ATTUNE Knee appears to provide greater stability than other implants I have used, which may be a contributing factor to these positive results.”

Secondly, a report² generated by DePuy Synthes summarized a series of studies across several countries with differing healthcare systems.  This report, entitled “The Impact of Implant Design on Hospital Length of Stay and Discharge Destination: Evidence Summary Report,” evaluated the connection between implant design and patient hospital length of stay (LOS), and encompassed some data that has been presented or accepted at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).^3-7 This retrospective review of five real-world evidence studies, conducted by DePuy Synthes in the US, UK, Germany, Italy and The Netherlands, was designed to evaluate whether patients treated with the ATTUNE Knee had a shorter hospital length of stay (LOS) versus a number of comparative implants. The report concluded that in each of these studies, the ATTUNE Knee patients were discharged from the hospital sooner than with the comparative implants used.^3-7 

Reducing LOS is recognized as an effective way to lessen the financial burden of elective orthopaedics by reducing resource utilization, thereby lowering the overall cost of care.⁸ In addition, reducing LOS may also positively impact patient satisfaction. Emerging evidence detailed in this report² suggests the ATTUNE Knee may facilitate earlier hospital discharge, with these studies observing a reduced length of stay between 0.19 and 4 days on average, depending on the comparative implants/countries compared against.^3-7 While differences in healthcare systems limit the direct comparison of these observed statistically significant improvements in LOS, this report highlights the positive impact the ATTUNE Knee may deliver in various rehabilitation settings.

Commenting on the LOS findings to which his Center also contributed, Dr. Meermans concluded, “While it’s important to acknowledge that many factors can contribute to differences in length of stay, the data seems to suggest that implant design may be an important factor to consider in total knee arthroplasty procedures. This latest evidence gives me greater confidence that the device could help hospitals cost-effectively keep pace with the growing total knee arthroplasty demand.”

These findings come at a time when healthcare systems are facing unprecedented challenges due to demographic shifts and increases in demand due to the predicted global growth of knee replacement procedures.⁹ It is increasingly important for healthcare providers to demonstrate improved clinical, economic and patient reported outcomes to help minimize the total cost per procedure while maintaining and, where possible, improving quality of care.

Torbjorn Skold, Vice President, DePuy Synthes EMEA Joint Reconstruction added: “I’m delighted that this data demonstrated that study patients receiving the ATTUNE Knee experienced positive outcomes related to the rate of return of functional outcomes and reduced length of stay, allowing these patients to get back to a positive quality of life.”

Notes to Editors

About the Length of Stay (LOS) Report “The Impact of Implant Design on Hospital Length of Stay and Discharge Destination: Evidence Summary Report”²

The purpose of this report was to summarize a series of 5 studies that were designed to evaluate whether patients treated with the ATTUNE Knee had a shorter LOS versus certain comparative implants. The studies were conducted in several countries with differing healthcare systems. All the studies in this report defined LOS as the primary endpoint. An additional study by Clement et al., (2017) conducted in Scotland also observed a statistically significant 1.2-day reduction (P<0.001) in LOS versus another leading knee system but is not included in this report as LOS was not the primary outcome.¹⁰

There are several important aspects of this report that limit the comparability of results among the studies and the generalizability to other institutions/countries. Due to factors within each country’s healthcare systems, baseline mean LOS will vary, which limits direct comparison of the means and differences between studies. Statistical analyses also differ by study as they controlled for different factors because of the feasibility of retrospective chart review/data collection at each site, which further limits the comparability of the results. This review however, was not intended to aggregate the data, it was to report each study in isolation and highlight the reductions in LOS seen in multiple healthcare settings following the adoption of the ATTUNE Knee.

Study summary

Study 1 examined insurance claims data across a range of US geographies and institution types (38 hospitals) including 1,178 US patients who received the ATTUNE Knee and 5,707 patients who received the Triathlon® Knee, with the patients receiving the ATTUNE Knee having a shorter average LOS (<0.19 day) compared to the Triathlon® Knee patients.  ATTUNE Knee patients were also 39% less likely to be discharged to a skilled nursing facility.³

Study 2 evaluated patients at a University Teaching Hospital in the UK, 238 of whom were implanted with an ATTUNE Knee, 332 with a SIGMA Knee and 149 with a Columbus® Knee.  Patients implanted with the ATTUNE Knee on average experienced a 0.8-day shorter LOS compared to SIGMA Knee patients and a 1-day reduction compared to patients treated with the Columbus® Knee. Both comparisons were statistically significant.⁴

Study 3 evaluated patients at a private German hospital, 85 of whom were implanted with the ATTUNE Knee compared to 85 implanted with the LCS Complete Knee System.  Patients in this study implanted with the ATTUNE Knee were discharged from hospital on average 2.1 days earlier than patients implanted with the LCS Complete Knee. This reduction in LOS was statistically significant.⁵

Study 4 evaluated two groups at a private Italian hospital: 100 patients implanted with the ATTUNE Knee and 100 patients who received a SIGMA Knee.  A statistically significant difference in LOS was observed: the patients implanted with an ATTUNE Knee were discharged from the hospital on average 4 days earlier than the patients implanted with a SIGMA Knee. ⁶

Study 5 evaluated two groups at a public hospital in The Netherlands: 100 patients implanted with the ATTUNE Knee and 100 patients implanted with the SIGMA Knee.  Both groups were treated with the same rehabilitation protocol.  Patients in this study who were implanted with the ATTUNE Knee were discharged from the hospital on average 0.67 days earlier than patients implanted with the SIGMA Knee. Similar to study 1,³ ATTUNE Knee patients were also less likely to be discharged to a rehabilitation center (referred to as a skilled nursing facility in the US).  For Study 5, the statistically significant improvements were achieved in a hospital environment with an established enhanced recovery program and a low baseline LOS.⁷

All the studies defined LOS as the primary endpoint. A copy of the full report can be found on ATTUNEevidence.com.

About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, interventional solutions and specialty surgery with an offering directed at delivering clinical and economic value to health care systems worldwide.

About DePuy Synthes

DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.

The third-party trademarks used herein are the trademarks of their respective owners.

© DePuy Synthes 2018. All rights reserved.

References

1. van Loon C, Meermans G, Baas N, Vergroesen D, van Kampen P, Dwyer K, Lesko J, Huey V. Early Recovery Rate After A New Design Total Knee Arthroplasty (TKA): A Prospective, Multicenter Cohort of 200 Cases. Poster Accepted to World Arthroplasty Congress April 19-21, 2018. Rome, Italy, Poster # P101.
2. The Impact of Implant Design on Hospital Length of Stay and Discharge Destination Evidence Summary Report. 090088-180413. Available at ATTUNEevidence.com. Accessed April 2018.
3. Etter K, Lerner J, Kalsekar I, de Moor C, Yoo A, Swank M. Comparative Analysis of Hospital Length of Stay and Discharge Status of Two Contemporary Primary Total Knee Systems. The Journal of Knee Surgery. 2017 Aug 25.
4. Mantel J, Corso KA, Wei D, Holy CE, Muehlendyck C, Jayakumar P, Higgins M, Westbrook A. Economic Effectiveness Of The ATTUNE® Knee System-Analysis Of Real World Hospital Length Of Stay And Incidence Of Early Complications. Value in Health. 2017 Oct 1;20(9): A579.
5. Brüggenjürgen B, Muehlendyck C, Gador L, Katzer A. Length of Hospitalisation After ATTUNE® Knee Joint Arthroplasty (TKA)-Results of A German Retrospective Database Analysis. Value in Health. 2017 Oct 1;20(9):A597.
6. Pipino G, Paragò V, Corso KA, Wigham R, Holy CE, Do Rego B. Economic Outcomes Of The ATTUNE® Knee System: Analysis Of Real World Length Of Stay In An Italian Hospital. Value in Health. 2017 Oct 1;20(9):A595.
7. Meermans G, Galvain T, Wigham R, Do Rego B, Schröer D. Comparative analysis investigating the impact of implant design on hospital length of stay and discharge destination in a Dutch hospital with an established enhanced recovery program. DSEM/JRC/0118/0984. Poster Accepted to ISPOR Annual Meeting May 19-23, 2018. Baltimore US. Presentation code PMD23.
8. Briggs TWR. A national review of adult elective orthopaedic services in England: Getting it right first time. Available at: https://www.boa.ac.uk/wp-content/uploads/2015/03/GIRFT-National-Report-Mar15..pdf. Accessed April 2018.
9. Patel A, Pavlou G, Mújica-Mota RE, Toms AD The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset. Bone & Joint J. 2015 Aug;97-B(8):1076-81.
10. Clement N, Brenkel I, Walmsley P. IMPROVED EARLY FUNCTIONAL OUTCOME WITH THE ATTUNE TOTAL KNEE REPLACMENT: A PROPENSITY SCORE MATCHED TRIAL. 2017. Poster session presented at British Association for Surgery of the Knee, Southport, United Kingdom.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the ATTUNE Knee System*. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes, the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

091374-180507

SOURCE DePuy Synthes

Related Links

http://www.depuysynthes.com

WARSAW, Ind., April 30, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced today that it has entered into a partnership agreement with Faith In Practice, a Houston-based non-profit organization that provides surgical, medical, dental and educational programs in Guatemala. Under the partnership, Zimmer Biomet will donate instrument sets and provide implants for Faith In Practice to place in inventory with the goal of improving access to total knee arthroplasty procedures for patients in underserved communities.

Through the partnership’s model, Faith In Practice will utilize Zimmer Biomet implants at the Las Obras Hospital in Antigua and Hilario Galindo Hospital in San Felipe, Retalhuleu, Guatemala.

“This is an outstanding partnership of two organizations that are focused on the health of those in need in developing countries such as Guatemala,” said Brian S. Parsley, M.D., lead orthopaedic surgeon and member of Faith In Practice’s board of directors. “Zimmer Biomet has been supportive of our medical mission work for many years, and this agreement will further our capacity to treat those patients in need and offer them an opportunity to walk comfortably, remain active and provide for their families. This partnership will allow our surgeons to reach out and help even more patients due to the availability of implants and equipment. Our surgeons are ecstatic about this relationship.”

“We are delighted to partner with Faith In Practice,” said Dan Williamson, Zimmer Biomet’s Group President, Joint Reconstruction. “This opportunity enables us to continue to provide our innovative products and solutions in a socially impactful manner and further expands our ongoing efforts to help improve the lives of people in underserved communities who typically do not have access to healthcare advancements.”

“We are incredibly grateful to Zimmer Biomet for making this commitment to serve those in great need in Guatemala. While Zimmer Biomet has always been generous in supporting medical volunteers who wish to serve those in need in developing nations, this new way of providing implants will leverage and expand its impact significantly. We applaud Zimmer Biomet’s efforts and are honored to be its first partner in this new way of providing care to those who otherwise would have no access,” said the Rev. Linda McCarty, President and Chief Executive Officer of Faith In Practice.

About Faith In Practice
The mission of Faith In Practice is to improve the physical, spiritual, and economic conditions of the poor in Guatemalathrough short-term surgical, medical, and dental mission trips and health-related educational programs. Faith In Practice’s life-changing medical mission is to minister to the poor, while providing a spiritually enriching experience for its volunteers. Each year, more than 1,300 US volunteers serve through Faith In Practice, covering their own costs, taking vacation time, to serve. They are joined by more than 1,000 Guatemalan volunteers and two non-profit Guatemalan hospitals to provide care to the poor of Guatemala. For more information, visit www.faithinpractice.org.

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmer.com

24 April 2018

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, announces that Spire Bushey Hospital in the UK, has completed Europe’s first robotics-assisted total knee replacement procedure using the NAVIO^◊ Surgical System.

Consultant Orthopaedic Surgeon Mr Richard Carrington, MBBS, FRCS (Orth), performed the first surgery using the Smith & Nephew JOURNEY^◊ II Total Knee System.

The Smith & Nephew NAVIO Surgical System is a next generation handheld robotics platform designed to aid surgeons with component positioning, ligament balancing and bone preparation – key factors that may drive implant survivorship.^1,2  NAVIO is designed to help the surgeon with surgical planning and balancing of the joint to the patient’s specific needs. The handheld instrumentation uses multiple control modes to help the surgeon accurately prepare the bone for implantation.

The small footprint of NAVIO allows for easy set up and portability. Furthermore, NAVIO does not require a preoperative image, such as a CT scan. This allows patients to receive the benefits of robotics-assistance without the extra steps, costs, and radiation associated with additional preoperative imaging.³

“We are proud to support Spire Bushey in being the first hospital in Europe to bring patients the benefits of a robotic-assisted total knee procedure using the NAVIO Surgical System,” said Massimiliano Colella, President Europe and Canada, Smith & Nephew. “It is an important innovation as 80% of all knee replacement surgeries globally are total knees⁴, and it is exciting that Spire’s patients can now benefit from the improvements in accuracy that robotics is designed to deliver.”

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew plc

References

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

About Spire Bushey Hospital

Working with leading consultants in their field, we have become the private hospital of choice for knee replacements in London and our region. Across both 2016 and 2017*, more knee replacements were carried out at Spire Bushey than any other private London hospital.  Our team of expert physiotherapists provide comprehensive pre-habilitation programmes to help strengthen the limb before surgery to improve recovery. They use the onsite gym and hydrotherapy pool to support patient rehabilitation following surgery.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}